Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.GenVec obtains grant for PEDF program
This grant valued at approximately $546,000 over two years, will support research being conducted at GenVec. Rick King, senior vice president of research at GenVec, said: “A key
This grant valued at approximately $546,000 over two years, will support research being conducted at GenVec. Rick King, senior vice president of research at GenVec, said: “A key
The combination with Amsterdam Molecular Therapeutics’s (AMT) adeno-associated virus (AAV) gene therapy platform potentially makes up a long-term treatment for this seriously debilitating disease with a single administration
The Anticoagulation Module is a part of Lumedx’s suite of integrated cardiovascular imaging and information management tools, delivering a robust and unified cardiovascular information systems solution. The Anticoagulation
Sierra Providence East Medical Center is located at 3280 Joe Battle Boulevard on the eastern side of El Paso. The hospital represents a total initial investment of $143.9
Terms of sale include $982,000 in cash payable to Cyberkinetics on or before July 1, 2008, and Cyberkinetics’s retention of approximately $570,000 in accounts receivable. Under the terms
Morphotek will apply its Libradoma technology to isolate and initially characterize candidate antibodies and the National Institute of Allergy and Infectious Diseases (NIAID) will further characterize the antibodies
This new global mega-study will involve close to 20,000 patients and requires provision of very sophisticated technological and statistical solutions, a key strength of Almac service offering. The
The new development agreement will be on percutaneous urinary catheters. Covalon and its partner have agreed upon a series of development milestones for which Covalon will be compensated.
The FDA approved the abbreviated new drug application based on Spear’s 318 patient study proving bioequivalence to Efudex for the precancerous actinic keratoses skin condition, the indication for
One study will be in previously untreated (naive) patients and the other in patients who failed prior treatment (relapsers and nonresponders), an area of great unmet medical need.